Eton Pharmaceuticals (ETON) vs Kiniksa Pharmaceuticals International (KNSA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Eton Pharmaceuticals (ETON) has outperformed Kiniksa Pharmaceuticals International (KNSA) over the past year, gaining 159.5% versus a gain of 104.5%. Over five years, ETON leads with a +953.4% price change compared with +580.9% for KNSA. Kiniksa Pharmaceuticals International is the larger company by market cap ($6.14 billion vs $1.56 billion), about 3.9 times the size.
On valuation, Eton Pharmaceuticals trades at a lower forward P/E (21.2x vs 48.7x for Kiniksa Pharmaceuticals International).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ETON | KNSA |
|---|---|---|
| Share price | $54.75 | $78.75 |
| Market cap | $1.56B | $6.14B |
| 1-day change | -0.24% | +1.01% |
| YTD return | +224.54% | +88.99% |
| 1-year return | +159.48% | +104.51% |
| 5-year return | +953.36% | +580.87% |
| P/E ratio (TTM) | 136.88 | 79.55 |
| Forward P/E | 21.22 | 48.69 |
| EPS (TTM) | $0.40 | $0.99 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $677.56M |
| Revenue growth (YoY) | — | +60.09% |
| Net income (latest FY) | — | $59.01M |
| Gross margin | — | 88.54% |
| Operating margin | — | 11.40% |
| Net margin | — | 8.71% |
| 52-week high | $66.37 | $82.94 |
| 52-week low | $14.27 | $35.20 |
| Distance from 52-week high | -17.51% | -5.05% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +29.68% | +24.44% |
| Average volume | 606.07K | 578.96K |
| Shares outstanding | 28.58M | 48.29M |
| Employees | 44 | 366 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Kiniksa Pharmaceuticals International is about 3.9 times larger than Eton Pharmaceuticals by market value ($6.14B vs $1.56B).
- ETON has outperformed KNSA by 55.0 percentage points over the past year.
- Eton Pharmaceuticals trades at a higher earnings multiple (136.9x vs 79.5x trailing P/E).
About Eton Pharmaceuticals
ETON stock →Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1.
Health Care · Biotechnology: Pharmaceutical Preparations · 44 employees
About Kiniksa Pharmaceuticals International
KNSA stock →Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 366 employees
ETON vs KNSA FAQ
Which is bigger, Eton Pharmaceuticals or Kiniksa Pharmaceuticals International?
Kiniksa Pharmaceuticals International (KNSA) is larger, with a market capitalization of $6.14B compared with $1.56B for Eton Pharmaceuticals (ETON).
Which stock has performed better over the past year, ETON or KNSA?
ETON returned +159.48% over the past 12 months, compared with +104.51% for KNSA (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, ETON or KNSA?
KNSA has the lower trailing P/E at 79.5, versus 136.9 for ETON. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Eton Pharmaceuticals and Kiniksa Pharmaceuticals International in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.